secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001193125-25-324768
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio raises $150M in private placement; appoints two new directors
---------------------------------------------------------------------

- Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.
- New/existing investors include RA Capital, Forbion, Frazier Life Sciences, Caligan, Logos, Venrock.
- Proceeds to advance telitacicept Phase 3 trials for myasthenia gravis and Sjögren's disease.
- Director Sarah Reed resigned; Andrew Levin (RA Capital) and Wouter Joustra (Forbion) appointed.
- Levin and Joustra receive standard director fees and option grants of 3,000 shares each.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/0001193125-25-324768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525324768/vor-20251215.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-324768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer